Background Hormone replacement therapy is associated with an increased thromboembolic
risk. The effects of testosterone (T) on coagulation markers in people assigned female at …

Background Although venous thromboembolism (VTE) is a recognized side effect of some
formulations of estrogen therapy, its impact in transgender people remains uncertain. The …

Background The transgender population that uses gender‐affirming hormone therapy
(GAHT) is rapidly growing. The (side) effects of GAHT are largely unknown. We examined …

An estimated 2-3% of US youth identify as transgender or gender non-conforming (hereafter
transgender). Transgender youth may suffer from gender dysphoria, a condition associated …

Background Feminizing and masculinizing hormone treatments are established components
of management in transgender patients. Exogenous hormones have been associated with …

Transgender and gender-expansive (TG) people–those who identify with a gender other
than their assigned sex at birth–frequently experience gender dysphoria, which is …

BACKGROUND Transgender women are female individuals who were recorded men at
birth based on natal sex. Supporting a person's gender identity improves their psychological …

Gender-affirming hormonal therapies are a critical component of the care of transgender
individuals. Transgender people are commonly prescribed estrogen or testosterone to …

Purpose: Given evidence from cisgender patients that sex hormones can impact risk for
some forms of cardiovascular disease (CVD), there are concerns regarding CVD among …

METHODS: This retrospective chart review was conducted at a pediatric hospital-associated
transgender health clinic. The primary outcome was incidence of arterial or venous …